Adaptive Biotechnologies vs Dianthus Therapeutics
Adaptive Biotechnologies (ADPT), health care, and Dianthus Therapeutics (DNTH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Dianthus Therapeutics is worth $4.9B on the stock market and Adaptive Biotechnologies $4.6B: Dianthus Therapeutics is valued at 6% more. Adaptive Biotechnologies's operating margin in its latest fiscal year was -20.6% and Dianthus Therapeutics's -8739%. Over the past year Adaptive Biotechnologies's share price has moved +103% and Dianthus Therapeutics's +119%.
Key facts
- Adaptive Biotechnologies market value
- $4.6B
- Dianthus Therapeutics market value
- $4.9B
- Adaptive Biotechnologies revenue
- $277MFY to 2025-12-31
- Dianthus Therapeutics revenue
- $2MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Adaptive Biotechnologies | Dianthus Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.6Blower | $4.9Bhigher |
| Revenue | $277Mhigher | $2Mlower |
| Earnings | -$59.5Mhigher | -$162.3Mlower |
| Employees | 624higher | 92lower |
| Total assets | $512.7Mlower | $530.9Mhigher |
| Valuation | ||
| P/E | — | — |
| P/S | 16.7lower | 2406higher |
| P/B | 26.1higher | 3.9lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -20.6%higher | -8739%lower |
| Balance sheet | ||
| Net assets | $218.8Mlower | $493.4Mhigher |
| Total liabilities | $287.7Mhigher | $37.5Mlower |
| Total debt | $131.2M | — |
| Cash on hand | $70.5Mhigher | $51.1Mlower |
| Price change | ||
| Today | +2.22%higher | -2.87%lower |
| 1 year | +103%lower | +119%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Polen Capital team<0.1% / <0.1%
Adaptive Biotechnologies only (2)
- Andreas Halvorsen1.8%
- Cathie Wood0.3%
Dianthus Therapeutics only (1)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Adaptive Biotechnologies / Dianthus Therapeutics). Who owns ADPT · Who owns DNTH
More on Adaptive Biotechnologies
Further comparisons
Adaptive Biotechnologies against its closest peers
Dianthus Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Adaptive Biotechnologies or Dianthus Therapeutics?
By market value, Dianthus Therapeutics is the larger: $4.9B against $4.6B for Adaptive Biotechnologies. By revenue in its latest fiscal year, Adaptive Biotechnologies is the larger: $277M against $2M for Dianthus Therapeutics.
Which has the higher operating margin?
Adaptive Biotechnologies: -20.6%, against -8739% for Dianthus Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Adaptive Biotechnologies and Dianthus Therapeutics?
In their latest 13F filings, Polen Capital team holds both.
Cite this page
Funkfolio, “Adaptive Biotechnologies vs Dianthus Therapeutics”, data as of 17 November 2026. https://funkfolio.com/compare/adpt-vs-dnth
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.